ZymoGenetics ZGEN
-
New Morningstar Analyst Report for Biogen Idec Inc
… Biogen well; Doug Williams now acts as head of research and development (previously head of research at Immunex and CEO of ZymoGenetics ) and Steve Holzman as head of corporate development (previously at Millennium and Infinity). Bruce Ross, a Bristol …
-
Our Top Five Biotech Acquisition Candidates… companies that have very robust pipelines in very popular areas. So for example, OSI and Abraxis in cancer, Crucell and Zymogenetics in infectious disease. And then also in MS, we saw Facet acquired by Abbott as well as Sanofi's acquisition of Genzyme …
popular areas. So for example, OSI and Abraxis in cancer, Crucell and Zymogenetics in infectious disease. And then also in MS, we saw Facet acquired by Abbott as well as Sanofi's acquisition of Genzyme--a lot -
Our Outlook for Health-Care Stocks
… keen on replacing the revenue stream that will be lost to generic competition during the next several years. Crucell CRXL, ZymoGenetics , King Pharmaceuticals KG, and Genzyme GENZ (among others) have either already been acquired or in the process of being …
-
Our Outlook for Health-Care Stocks
… activity in the drug industry, most notably a saga surrounding Genzyme GENZ and takeouts of two smaller biotech firms Zymogenetics ZGEN and Crucell CRXL. With big pharma on the prowl to replace the revenue stream that will be lost to generic competition …
-
Bristol to Acquire ZymoGenetics
… announced that it will acquire ZymoGenetics ZGEN for $885 million ($735 million ..... our fair value estimate for ZymoGenetics to reflect this offer price ..... represents an attractive price for ZymoGenetics at a premium to our previous …
-
New Morningstar Analyst Report - ZymoGenetics , Inc.
… In addition to interest payments, ZymoGenetics will have to forfeit 2% of U.S ..... rights to IL-21 and a new partner for ZymoGenetics has yet to be named, casting uncertainty ..... share of the global hemostat market. ZymoGenetics ' expertise developing therapeutic …
-
Recothrom is off to a slow start, but we find ZymoGenetics' hep C candidate especially promising.
… In addition to interest payments, ZymoGenetics will have to forfeit 2% of U.S ..... rights to IL-21 and a new partner for ZymoGenetics has yet to be named, casting uncertainty ..... share of the global hemostat market. ZymoGenetics ' expertise developing therapeutic …
-
ZGEN Cuts Workforce, Cancer Program
ZymoGenetics ZGEN announced Thursday its intent to reduce ..... in light of cash troubles. Although ZymoGenetics ' restructuring will slow the firm ..... in savings each year as a result. ZymoGenetics will halt ongoing research activities …
-
Bristol Signs on to ZymoGenetics Drug
On Monday, ZymoGenetics ZGEN and Bristol-Myers Squibb BMY announced ..... maintaining our fair value estimate. ZymoGenetics will collect an up-front cash ..... the collaboration could bring ZymoGenetics more than $1 billion in milestone …
-
ZymoGenetics under Review
We're placing ZymoGenetics ZGEN under review. We expect the firm will need to tap the equity markets in 2009 to fund the development of its pipeline. Given the …